NEWTON, Mass.--(BUSINESS WIRE)--Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non- systemic oral protein therapeutics to treat metabolic and orphan diseases, today announced that the company will present data from a completed Phase 2 study of ALLN-177 (NCT02289755), its lead product for the treatment of hyperoxaluria, at the American Society of Nephrology (ASN) Kidney Week 2015, being held November 3-8, 2015 at the San Diego Convention Center in San Diego.
Help employers find you! Check out all the jobs and post your resume.
